Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D. LeBlanc
Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma
Haematologica
Hematology
Climate Change Effects on Forests: A Critical Review
Related publications
Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone (LR-CD) for Untreated Low-Grade Non-Hodgkin Lymphoma Requiring Therapy
American Journal of Hematology
Hematology
Treatment With Combination of Lenalidomide and Rituximab Achieves Durable Responses in a Long Term Follow Up of Patients With Indolent Non-Hodgkin's Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma
British Journal of Haematology
Hematology
Pegfilgrastim in Primary Prophylaxis of Febrile Neutropenia Following Frontline Bendamustine Plus Rituximab Treatment in Patients With Indolent Non-Hodgkin Lymphoma: A Single Center, Real-Life Experience
Supportive Care in Cancer
Oncology
Study of Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas and Mantle Cell Lymphoma Receiving Bendamustine and Rituximab
British Journal of Haematology
Hematology
Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas Receiving Bendamustine and Rituximab
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
